2019
Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy.
OʼMeara T, Kong Y, Chiarella J, Price RW, Chaudhury R, Liu X, Spudich S, Robertson K, Emu B, Lu L. Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 514-522. PMID: 31714431, PMCID: PMC6857839, DOI: 10.1097/qai.0000000000002187.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyNeuropsychological performanceAntiretroviral therapyViral suppressionHIV infectionNeurocognitive dysfunctionExo-miRNAsEarly infection groupCentral nervous systemSystemic viral suppressionTyrosine receptor kinaseInfection groupChronic infectionPLWHCross-sectional examinationNervous systemEarly infectionNeuropsychological scoresInfectionConsistent findingNeuropsychological batteryHIVNeurodegeneration pathwaysDysfunctionTherapy
2018
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. New England Journal Of Medicine 2018, 379: 645-654. PMID: 30110589, DOI: 10.1056/nejmoa1711460.Peer-Reviewed Original ResearchConceptsPhase 3 studyHIV-1 infectionViral loadBackground regimenVirologic failureAdverse eventsWeek 25Multidrug-resistant HIV-1 infectionMDR HIV-1 infectionMean baseline viral loadMultidrug-resistant HIV-1Human immunodeficiency virus type 1Immunodeficiency virus type 1Control periodMultiple antiretroviral therapiesViral load decreaseCommon adverse eventsMean CD4 countPrimary end pointSerious adverse eventsBaseline viral loadProportion of patientsHIV-1 RNALimited treatment optionsVirus type 1
2015
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults
Ishida JH, Burgess T, Derby MA, Brown PA, Maia M, Deng R, Emu B, Feierbach B, Fouts AE, Liao XC, Tavel JA. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults. Antimicrobial Agents And Chemotherapy 2015, 59: 4919-4929. PMID: 26055360, PMCID: PMC4505204, DOI: 10.1128/aac.00523-15.Peer-Reviewed Original ResearchConceptsHealthy adultsPlacebo groupAdverse eventsMonoclonal antibodiesDose-proportional pharmacokineticsMost adverse eventsDose-escalation studyMonoclonal antibody therapyProportion of subjectsHuman monoclonal antibodyOverall pharmacokinetic profileLife-threatening diseasePhase 1Transplant recipientsCytomegalovirus infectionAntibody therapyImmunogenicity profileMultiple dosesAntibody responseImmunocompromised individualsPharmacokinetic profileSusceptible populationAdultsHost targetsTherapy
2014
Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease
Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, Deeks SG, McCune JM. Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease. PLOS ONE 2014, 9: e85613. PMID: 24465619, PMCID: PMC3897457, DOI: 10.1371/journal.pone.0085613.Peer-Reviewed Original ResearchConceptsT cell subpopulationsT cellsCell subpopulationsViral loadCMV-specific T-cell responsesNaïve T cell numbersLong-term viral suppressionIncrease of CD4Effective antiretroviral treatmentT cell frequenciesUndetectable viral loadT cell numbersT-cell depletionT cell responsesT-cell phenotypeNormal immune systemT cell populationsLow Ki67 expressionT cell functionIndependent homeostatic regulationDifferent proliferative responsesAntiretroviral therapyViral suppressionHIV diseaseAntiretroviral treatment
2012
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Research & Therapy 2012, 14: r6. PMID: 22225620, PMCID: PMC3392792, DOI: 10.1186/ar3554.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArea Under CurveArthritis, RheumatoidChemokine CXCL13DiarrheaDose-Response Relationship, DrugDouble-Blind MethodFemaleHeadacheHumansInjections, IntravenousInjections, SubcutaneousLymphotoxin-alphaMaleMetabolic Clearance RateMiddle AgedSignal TransductionTreatment OutcomeYoung AdultConceptsRA patientsAdverse eventsDose phaseClinical activityBiologic activityMedian Disease Activity ScoreMajority of AEsLymphotoxin αACR70 response ratesActive RA patientsRA disease activityDisease Activity ScorePlacebo-controlled trialSerious adverse eventsRheumatoid arthritis (RA) pathogenesisC-reactive proteinNovel monoclonal antibodyDisease activityPlacebo groupArthritis pathogenesisSerum CXCL13Activity scoreClinical effectsMultiple dosesT cells
2011
HIV disease progression correlates with the generation of dysfunctional naive CD8low T cells
Favre D, Stoddart CA, Emu B, Hoh R, Martin JN, Hecht FM, Deeks SG, McCune JM. HIV disease progression correlates with the generation of dysfunctional naive CD8low T cells. Blood 2011, 117: 2189-2199. PMID: 21200021, PMCID: PMC3062328, DOI: 10.1182/blood-2010-06-288035.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsCalcium SignalingCD8-Positive T-LymphocytesDisease ProgressionHIV InfectionsHumansIn Vitro TechniquesInterferon alpha-2Interferon-alphaInterleukin-2Major Histocompatibility ComplexMART-1 AntigenMiceMice, SCIDMice, TransgenicMiddle AgedP38 Mitogen-Activated Protein KinasesPhosphorylationReceptors, Antigen, T-CellRecombinant ProteinsSignal TransductionThymus GlandUp-RegulationViral LoadConceptsPeripheral blood mononuclear cellsT cellsHIV diseaseHIV infectionSCID-hu Thy/Liv mouse modelMajor histocompatibility complex class ICD8low T cellsProgressive HIV diseaseHIV disease progressionHistocompatibility complex class IBlood mononuclear cellsInterferon-α treatmentAntigen-presenting cellsComplex class IT cell receptor complexCD8β chainNaive compartmentΑ treatmentMononuclear cellsDisease progressionMouse modelStromal cellsLow expressionClass IMHC
2008
Relationship between T Cell Activation and CD4+ T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy
Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T Cell Activation and CD4+ T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. The Journal Of Infectious Diseases 2008, 197: 126-133. PMID: 18171295, PMCID: PMC3466592, DOI: 10.1086/524143.Peer-Reviewed Original ResearchConceptsUndetectable plasma HIV RNA levelsT cell activationPlasma HIV RNA levelsHIV RNA levelsHIV-negative subjectsHigh LPS levelsCell activationCell countAntiretroviral therapyLPS levelsHigh T-cell activation levelsHIV-specific immune responsesT cell activation levelsUntreated human immunodeficiency virusPlasma lipopolysaccharide levelsRNA levelsHIV-seropositive individualsT-cell countsT cell lossHuman immunodeficiency virusAbsence of therapyActivation levelsCells/Measurable viremiaMucosal translocation
2005
Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment
Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG. Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment. Journal Of Virology 2005, 79: 14169-14178. PMID: 16254352, PMCID: PMC1280210, DOI: 10.1128/jvi.79.22.14169-14178.2005.Peer-Reviewed Original ResearchConceptsHIV-specific T cellsT cellsT cell activationHIV diseaseImmune activationHuman immunodeficiency virus (HIV) replicationAdvanced HIV diseaseDrug-resistant viremiaGeneralized immune activationHIV-specific ILMultidrug-resistant HIVQuiescent immune systemActive antiretroviral therapyCytokine flow cytometryT cell controlHigh-level viremiaLow-level viremiaPresence of HIVT cell subsetsHuman immunodeficiency virusImmunodeficiency virus replicationT cell subpopulationsAbsence of therapyPresence of therapyAntiretroviral therapy